These results suggest that an increase in EGFR copy number is prognostically harmful in NSCLC patients, but EGFR-TKI agents target mainly tyrosine kinase receptor activity and may not be effective in patients with a significant increase in EGFR copy number. Here, NTRK1 is linked to non-small cell lung carcinoma.